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Very late antigen-1 Marks 
Functional Tumor-resident 
cD8 T cells and correlates with 
survival of Melanoma Patients
Timothy Murray, Silvia A. Fuertes Marraco, Petra Baumgaertner, Natacha Bordry, 
Laurène Cagnon, Alena Donda, Pedro Romero, Grégory Verdeil and Daniel E. Speiser*
Ludwig Cancer Research, Department of Oncology, University of Lausanne, Lausanne, Switzerland
A major limiting factor in the success of immunotherapy is tumor infiltration by 
CD8+ T cells, a process that remains poorly understood. In the present study, we 
characterized homing receptors expressed by human melanoma-specific CD8+ T cells. 
Our data reveal that P-selectin binding and expression of the retention integrin, very 
late antigen (VLA)-1, by vaccine-induced T cells correlate with longer patient survival. 
Furthermore, we demonstrate that CD8+VLA-1+ tumor-infiltrating lymphocytes (TILs) 
are highly enriched in melanoma metastases in diverse tissues. VLA-1-expressing TIL 
frequently co-express CD69 and CD103, indicating tissue-resident memory T cells 
(TRM) differentiation. We employed a mouse model of melanoma to further characterize 
VLA-1-expressing TIL. Our data show that VLA-1+ TRM develop in murine tumors within 
2 weeks, where they exhibit increased activation status, as well as superior effector 
functions. In addition, in vivo blockade of either VLA-1 or CD103 significantly impaired 
control of subcutaneous tumors. Together, our data indicate that VLA-1+ TRM develop 
in tumors and play an important role in tumor immunity, presenting novel targets for the 
optimization of cancer immunotherapy.
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inTrODUcTiOn
CD8+ T cells have the capacity to recognize and kill tumor cells. The intensive development of 
T cell-based cancer immunotherapies over the past two decades has demonstrated remarkable 
therapeutic potential in both animal models and humans (1–6). However, complete tumor regres-
sion is seen in only a minority of patients, highlighting the need for better understanding and 
optimization of immunotherapeutic tools.
There is significant evidence that endogenous antitumor T cell responses improve clinical 
outcome, provided that T cells home efficiently to tumor and are retained there (7). However, 
numerous groups have reported discrepancies between the chemoattractants present within solid 
tumors and the corresponding homing receptors expressed by tumor-specific T cells (8–12). 
Abbreviations: TIL, tumor-infiltrating lymphocytes; TILN, tumor-infiltrated lymph nodes; dLN, tumor-draining lymph 
node; TEM, effector memory T cell; TRM, tissue-resident memory T cells; CpG, deoxycytidyl-deoxyguanosine; Melan-A 
(Melan-A/MART-1), melanoma antigen recognized by T cells; TCR, T cell receptor.
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Importantly, these discrepancies can be overcome by engineering 
homing receptor expression in tumor-specific T cell populations 
(9, 12, 13) or by delivery of chemoattractants to the tumor 
microenvironment (10, 14). These studies provide intriguing 
prospects for optimization of cancer immunotherapies in the 
future.
Despite the established importance of T cell homing for 
tumor immunity, most studies have been limited to the analysis 
of chemokine receptors. Such studies have implicated specific 
chemokine receptors, including CXCR3 and CCR4 (11, 15), 
as being important for tumor infiltration by T cells. However, 
lymphocyte homing involves numerous families of cell surface 
receptors, including selectins, selectin ligands, and integrins, 
in addition to chemokine receptors. Further work is urgently 
needed to better characterize the role of these players in tumor 
infiltration by T cells.
Tissue-resident memory T cells (TRM) have recently been iden-
tified as a unique T cell subset that resides within non-lymphoid 
tissues in murine models of virus infection and are typically iden-
tified by co-expression of the surface markers, CD69 and CD103 
(16–18). These cells are long lived, have high functional capacity, 
and are essential for efficient pathogen control at tissue barriers 
(19). The role of TRM in cancer, however, remains unclear. Several 
recent reports indicate that the presence of CD103+ tumor-
infiltrating lymphocytes (TILs) in various tumors correlates with 
favorable clinical outcome (20–22).
In the present study, we sought to broadly characterize the 
repertoire of homing receptors expressed by melanoma-specific 
CD8 T cells from patients with advanced disease, in circulation as 
well as in metastatic lesions. We further studied possible implica-
tions of homing receptor expression for tumor-infiltrating CD8 
T cells using a mouse model of melanoma.
MaTerials anD MeThODs
Melanoma Patients
Blood and tumor tissue were obtained as part of the LUD00-
018 Phase I clinical trial (Trial Number NCT00112229) at the 
Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne. 
The study was conducted according to the relevant regulatory 
standards, upon approval by Swissmedic (the regulatory agency 
of Switzerland) and the “Commission d’Ethique de la Recherche 
Clinique de la Faculté de Biologie et de Médecine, Université 
de Lausanne,” which also approved the use of specimens from 
healthy volunteers. Patients were enrolled upon written informed 
consent. The trial involved serial monthly subcutaneous vaccina-
tions of stage III/IV melanoma patients with peptides melanoma 
antigen recognized by T cells (Melan-A) ± Tyrosinase, together 
with deoxycytidyl-deoxyguanosine (CpG) 7909 and Montanide. 
Eighteen patients were included in the present study. These patients 
had a median duration of clinical follow-up of 107 months.
human cell Preparation and  
Flow cytometry
Peripheral blood mononuclear cells (PMBC) were directly iso-
lated from whole blood and stored in liquid nitrogen. Human 
tumor tissue was manually dissociated to yield a single cell 
 suspension, which was cryopreserved on the same day as the sur-
gery was performed. Frozen PBMC were thawed and incubated 
in RPMI with 10% FCS at 37°C overnight prior to analysis. CD8+ 
cells were enriched by negative selection with a magnetic bead 
system (StemCell, EasySep kit). Following CD8 enrichment, cells 
were first stained for 20 min at 4°C with APC-labeled Melan-A 
peptide-MHC tetramers (TCMetrix), followed by staining for 
surface markers (including CD8, CCR7, CD45RA, and homing 
receptors) for 20 min at room temperature. Ligands for E- and 
P-Selectin were detected by incubating cells with recombinant 
E- or P-selectin (R&D) in HBSS for 20 min at 4°C, followed by 
staining with FITC-labeled anti-human CD62E/P (R&D) at the 
same time as other surface antigens. Finally, cells were stained 
for 20 min at 4°C with LIVE/DEAD Aqua (Life Technologies) for 
discrimination of dead cells. Anti-human monoclonal antibod-
ies were purchased from BD (CD11a, CD49a, CD49b, CXCR3), 
Biolegend (CCR1, CCR2, CCR4, CCR5, CCR7, CCR10, CD8, 
CD29, CD49d, CD103, CX3CR1), Beckman Coulter (CD14, 
CD16, CD45RA), or eBioscience (CXCR2, CD62L). All data 
were acquired on a Beckman Coulter Gallios flow cytometer, and 
analysis was performed using FlowJo software.
Mouse Tumor Model
CD45.2+ C57BL/6 mice between 6 and 10 weeks of age were used 
as host mice in all experiments. B16-F10 mouse melanoma cells 
were electroporated with an Ova-encoding plasmid and selected 
based on G418 resistance (23). B16-Ova and E.G7 cells were cul-
tured for at least 5 days in RPMI, 10% FCS, prior to subcutaneous 
injection of 2 × 105 cells into the shaved flank skin of recipient 
mice. CD45.1+ OT-1 mice were sacrificed and lymphocytes 
pooled from lymph nodes and spleen before retro-orbital injec-
tion (i.v.) of 1 × 106 OT-1 T cells into recipient mice. 10 μg Ova 
peptide (SIINFEKL) and 50 μg CpG in 100 μl PBS were injected 
subcutaneously on the opposite flank to the tumor in order to 
immunize the mice. Tumor volume was measured according 
to length, width, and height using Vernier calipers from day 5 
following tumor engraftment and every 2–3  days thereafter. 
The end-point for sacrifice of tumor-bearing mice was a tumor 
volume of 1 cm3, according to the Swiss regulations.
In Vitro stimulation and  
expansion of OT-1 cells
Splenocytes from CD45.1+ OT-1 mice were isolated as described 
above. Cells were then stimulated with anti-CD3 (1 μg/ml), anti-
CD28 (0.1 μg/ml), and recombinant IL-2 (20  IU/ml) for 48  h. 
Stimulated cells were harvested, washed, counted, and resus-
pended in medium containing 20 ng/ml IL-15. Cells were then 
expanded for a further 4 days, splitting as necessary. Immediately 
prior to adoptive transfer, live CD8+ cells were sorted on a BD 
FACS Aria and counted. Each mouse received 5 ×  105  cells in 
PBS i.v.
In Vivo Blockade of integrins
Function-blocking antibodies against mouse very late antigen 
(VLA)-1 (clone Ha31/8) and CD103 (clone M290) or isotype 
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control antibodies were purchased in “No Azide, Low Endotoxin” 
format from BD (VLA-1) and Bioxcell (CD103). Two hundred 
fifty microgram was injected intraperitoneally (i.p.) on days 6, 11, 
and 16 following tumor engraftment.
Mouse cell Preparation and Flow 
cytometry
Tumors, lymph nodes, and spleens were dissected immediately 
after sacrifice of tumor-bearing mice. Tumor tissue was dissoci-
ated manually prior to enzymatic digestion (Mitenyi Tumor 
Dissociation kit). Lymph node and spleen tissue was passed 
through a 100-μm filter and washed twice with PBS before 
analysis. Anti-mouse antibodies were provided either by the Flow 
Cytometry Facility of the Ludwig Cancer Research Institute or 
purchased from BD (CD49a, CD103, CD223) or Biolegend (IFNγ 
and PD1). Data were acquired on a Beckman Coulter Gallios and 
analysis performed with FlowJo software.
In Vitro stimulation assay
Lymphocytes from mouse tumor tissue were enriched by Ficoll 
separation before stimulation assays. Cells were incubated for 
5 h at 37°C in the presence of PMA (10 ng/ml) and Ionomycin 
(500 ng/ml). Brefeldin A (BD GolgiPlug) was added to the cul-
tures after 1 h in order to stain for intracellular cytokines.
statistics and analysis
Overall survival (OS) and disease-free survival (DFS) were 
defined as the time between enrollment in the LUD00-018 Phase 
I clinical trial and latest follow-up/death or relapse, respectively. 
Correlation between gene expression and OS was assessed by 
Spearman’s rank correlation coefficient, and the significance of 
Kaplan–Meier survival analysis was assessed by the Log-rank test, 
as is standard. Significance of single comparisons was assessed 
using the Mann–Whitney test, multiple comparisons using one-
way ANOVA, and tumor growth curves using multiple unpaired 
t-tests (corrected for multiple comparisons). GraphPad Prism 
was used for all graphs and statistics. Tree Star software was used 
for hierarchical clustering of expression data (Figures 1C,D).
resUlTs
homing receptor expression Profiling 
of circulating Melanoma-specific cD8+ 
T cells from Peptide-Vaccinated 
Metastatic Melanoma Patients
We have previously shown that subcutaneous vaccination of 
stage III–IV melanoma patients with the mixture of Melan-A 
peptide, CpG-containing oligodeoxynucleotide, and Montanide 
induces large numbers of circulating Melan-A-specific CD8+ 
T cells in the majority of patients treated (24). We analyzed 
the expression of a broad array of homing receptors (selected 
based on their established role in the migration of CD8 T 
cells from existing literature) on total and Melan-A-specific 
circulating CD8 T cells from these patients by flow cytometry. 
Melan-A-specific cells were identified by tetramer staining and, 
as expected, were mostly of effector memory (TEM) differentia-
tion status (Figure 1A). The expression of a panel of 17 homing 
receptors, including selectins, selectin ligands, chemokine 
receptors, and integrins, was then profiled on Melan-A-specific 
and “total” CD8+ TEM cells (representative examples shown in 
Figure 1B). The quantity of patient material was limited in some 
cases; therefore, we carried out an initial screen in which all 
homing receptors were analyzed on four patients (Figure 1C). 
The results of this first screen gave us an initial insight into which 
homing receptors were expressed by Melan-A-specific T cells. 
In addition, hierarchical clustering highlighted several analytes 
that were highly expressed by Melan-A-specific CD8+ TEM cells 
compared with total TEM cells from either healthy donors or 
patients, including: CX3CR1, CD62P-ligands, CD62E-ligands, 
CD62L, VLA-1, VLA-2, and VLA-4. Expression of selected 
analytes was subsequently investigated across a cohort of 18 
patients. Unsupervised hierarchical clustering of the expression 
data from this second screen showed that vaccine-induced 
Melan-A-specific TEM cells from melanoma patients display a 
homing receptor expression signature that is distinct from TEM 
cells derived from the blood of healthy donors or the total TEM 
cell pool from patient blood (Figure 1D). In addition, this sec-
ond screen confirmed that certain receptors, such as CX3CR1, 
CD62L, several β1 integrins (VLA-1, VLA-2, and VLA-4), as 
well as ligands for E- and P-selectin, were abundantly expressed 
by Melan-A-specific CD8+ T cells relative to non-specific cells. 
Other analytes, such as CCR5 and CXCR3, were expressed at low 
levels on Melan-A-specific cells.
P-selectin Binding and expression of 
Vla-1 by circulating Melanoma-specific 
cD8+ T cells correlate with survival of 
Vaccinated Patients
Among those homing receptors expressed on Melan-A-specific 
CD8+ T cells, some were highly differentially expressed between 
individual patients (representative examples in Figure  2A). In 
order to assess the potential significance of differentially expressed 
markers, we interrogated the homing receptor expression data 
against two clinical parameters: OS and DFS. Interestingly, when 
the vaccine-induced, Melan-A-specific T cells were considered, 
highly significant correlations were found between OS and the 
expression of the retention integrin, VLA-1 (α1β1) (Figure 2B), 
and P-selectin (CD62P) binding (Figure  2C). We grouped 
patients into “high” (greater than median) or “low” (less than 
median) expression of VLA-1 (Figures 2D,F) or P-selectin bind-
ing (Figures 2E,G). In both cases, Kaplan–Meier survival analysis 
demonstrates significantly longer OS of patients in which Melan-
A-specific T cells exhibited “high” expression compared with 
“low” expression (Figures 2D,E). The median OS of VLA-1 “high” 
patients was 90.8 months, in contrast to 29.4 months for VLA-1 
“low” patients. Similarly, “high” P-selectin-binding patients had 
a longer median OS (98.8  months) as compared to patients in 
the “low” P-selectin-binding group (23.2  months). Statistically 
significant associations were also observed between both markers 
FigUre 1 | homing receptor expression profiling of circulating, melanoma-specific cD8+ T cells from peptide-vaccinated metastatic melanoma 
patients. (a) Cryopreserved peripheral blood mononuclear cells isolated from the blood of vaccinated patients were cultured overnight and enriched for CD8+ cells 
prior to flow cytometric staining. CD8+ cells were stained with Melan-A tetramers, followed by fluorescently labeled antibodies against surface markers of T cell 
differentiation status (CCR7 and CD45RA) as well as homing receptors. (B) Representative histograms for several analytes on “total” or “Melan-A-specific” effector 
memory CD8+ T cells. (c) Heat map showing the initial screen for homing receptor expression on circulating Melan-A-specific CD8+ TEM cells from four vaccinated 
patients compared to the patients’ total TEM and to total TEM in three healthy donors. (D) Heat map showing the second screen for homing receptor expression on 
circulating Melan-A-specific CD8+ TEM cells from 18 vaccinated patients. Numbers on FACS plots indicate percentage positive cells within each gate (a) or 
percentage positive cells (B).
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and prolonged DFS of the patients (Figures 2F,G). Importantly, 
the associations between survival and VLA-1 expression or 
P-selectin-binding were restricted to the Melan-A-specific pool. 
No differences in the expression of either analyte were observed 
between “total” TEM cells of patients with “longer than” or “shorter 
than” median OS (Figures 2H,I).
cD8+ TrM cells That express Vla-1 
are highly enriched in human 
Melanoma Metastases compared 
to Blood circulation
We, next, interrogated the homing profiles of CD8+ T cells within 
the TIL pool of metastatic melanoma lesions from the same 
cohort of patients. We hypothesized that receptors that contribute 
to tumor homing would likely be expressed by a large proportion 
of cells that successfully infiltrate and remain within the tumor. 
Thus, we investigated the expression of the same panel of homing 
analytes on CD8+ T cells derived from melanoma metastases in 
various organs including skin, brain, and lung.
As expected, tumor-infiltrating T cells were mostly of effec-
tor memory differentiation status with very few naïve cells 
(Figure  3A). Certain activation markers, such as CXCR3 and 
CD69, were broadly expressed, whereas L-selectin expression 
was seen on very few cells (Figure S1 in Supplementary Material). 
P-selectin binding by CD8+ TIL was low in comparison with cir-
culating CD8+ cells (Figure 3B), despite the correlation we had 
previously observed between P-selectin binding of circulating 
Melan-A-specific T cells and patient survival. This may reflect a 
down-modulation of P-selectin ligands following extravasation 
FigUre 2 | P-selectin binding and expression of Vla-1 by circulating melanoma-specific cD8+ T cells correlate with survival of vaccinated patients. 
(a) Representative histograms illustrating highly differential expression of VLA-1 (patient numbers LAU205 and LAU1164) and binding to P-selectin (patient numbers 
LAU1129 and LAU1164) by Melan-A-specific CD8+ TEM cells. (B,c) Correlation between expression of VLA-1 (B) or P-selectin binding capacity (c) of Melan-A-
specific CD8+ TEM cells and overall patient survival. (D,e) Kaplan–Meier overall survival analysis of patients with Melan-A-specific effector memory CD8+ T cells 
displaying greater than (“high”) or less than (“low”) median expression of VLA-1 (D) or P Selectin binding (e). (F,g) Kaplan–Meier disease-free survival analysis based 
on the T cell’s “high” or “low” expression of VLA-1 (F) or P-selectin binding (g). (h,i) Expression of VLA-1 (h) or P-selectin binding (i) by total or Melan-A-specific 
CD8+ TEM cells from patients with greater than or less than median overall survival. (B,c) Spearman’s rank correlation coefficient. (D–g) Log-rank (Mantel–Cox) test. 
(h,i) **P < 0.01 (two-tailed Mann–Whitney test).
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from blood. In contrast, VLA-1-expressing CD8+ cells were 
highly enriched in TIL relative to circulating cells, irrespective 
of the organ in which the metastasis arose (Figure 3C). We also 
analyzed CD8+ T cells derived from tumor-infiltrated lymph 
nodes (TILN) as well as CD4+ TIL and found no such enrichment 
for VLA-1 expression, suggesting a homing mechanism unique 
to CD8+ cells in the tumor microenvironment (Figure  3C). 
Interestingly, VLA-1 was frequently co-expressed with archetypal 
markers of TRM differentiation, including CD69 and integrin 
CD103 (16–18) (Figure 3D). Indeed, the co-expression of both 
VLA-1 and CD103 was almost entirely absent from all other 
cellular compartments analyzed (Figure 3E). These data suggest 
a specialized migratory phenotype specific to CD8+ T cells that 
successfully infiltrate and remain within melanoma metastases of 
diverse tissue origin.
in subcutaneous Murine Tumors, cD8+ Til 
Display an integrin expression Profile That 
is Unique to the Tumor Microenvironment 
and is Dependent on subcutaneous 
immunization
In order to further investigate integrin function in the context of 
antitumor immunity by CD8+ T cells, we chose to use a mouse 
model of melanoma for the next phase of this study. Our initial 
aim was to determine whether the VLA-1+CD103+ phenotype 
seen on CD8+ TIL from human melanoma was present on TIL 
derived from mouse melanoma. This would imply that similar 
mechanisms of retention and/or survival of T cells within tumors 
are conserved between human and mouse, and that murine 
models provide a relevant pre-clinical system.
FigUre 3 | cD8+ T cells expressing Vla-1 and other integrins are highly enriched in human melanoma metastases compared to blood circulation. 
(a) Representative dot plot illustrating the predominantly TEM differentiation status of the CD8+ TIL analyzed in this study. (B) Representative histograms and 
quantification of P-Selectin binding by CD8+ TEM cells isolated from blood circulation and melanoma tumors. (c) Representative dot plots of VLA-1 and CD103 
expression on CD8+ TEM cells derived from melanoma metastases in skin, lung, and brain, blood circulation, metastatic lymph nodes (TILN), and tumor-derived CD4+ 
T cells. (D) Representative dot plot showing expression of TRM markers, CD69 and CD103, by VLA-1-expressing TIL. (e) Quantification of cells co-expressing VLA-1 
and CD103 in the cellular compartments indicated. Numbers on FACS plots represent percentage cells in each gate (a,c). (D) **P < 0.01, ***P < 0.005 (One-way 
ANOVA, Tukey’s multiple comparisons test).
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We carried out subcutaneous engraftment of Ova-expressing 
B16 melanoma cells in the flank of C57BL/6 mice (day 0), fol-
lowed by adoptive transfer of 1 × 106 OT-1 T cells on day 7, and 
immunization with Ova peptide and CpG on day 8. Mice were 
sacrificed on day 14 or day 21 and integrin expression was ana-
lyzed on CD8+ T cells derived from tumor, tumor-draining lymph 
nodes (dLN), and spleen (Figure 4A). At day 14, OT-1 TIL exhib-
ited VLA-1 expression comparable with that seen in dLN and 
spleen and were negative for CD103. By day 21, however, VLA-1 
expression was observed on a large majority of OT-1 TIL, and 
up to 50% of these cells displayed the VLA-1+CD103+ adhesion 
signature that we had previously observed in human melanoma 
metastases (Figures 4A,B). This phenotype was entirely absent 
from OT-1 T cells derived from either spleen or tumor-draining 
lymph nodes at both time points (Figures 4A,B).
We also observed expression of VLA-1 and CD103 on 
endogenous CD8+ TIL, but to a significantly lesser extent than 
in the OT-1 compartment (Figures  4B,C). It is likely that the 
proportion of endogenous TIL responding to antigen is signifi-
cantly lower than in the OT-1 T cell pool, which responds to the 
immunodominant OVA epitope in B16-OVA tumor cells. There 
are good reasons to assume that the intratumoral induction of 
VLA-1 and CD103 expression is, in part, dependent on efficient 
antigen recognition within the tissue, as this process has been well 
described in both cases (25–27).
In order to establish whether intratumoral integrin expression 
by T cells is specific to the melanoma microenvironment, we 
engrafted mice subcutaneously with an Ova-expressing mouse 
lymphoma cell line, E.G7. Despite the distinct tissue origin of this 
tumor cell line, OT-1 TIL showed a similar integrin-expression 
profile to that seen in melanoma tumors (Figure 4D), suggesting 
a general mechanism of homing or retention within subcutane-
ous tumors.
Finally, we addressed the question of whether intratumoral 
integrin expression was dependent on the context of T cell 
priming. We engrafted mice with B16-Ova tumors and, rather 
FigUre 4 | in subcutaneous murine tumors, cD8+ Til display an integrin-expression profile that is unique to the tumor microenvironment and is 
dependent on subcutaneous immunization. (a) Representative dot plots of VLA-1 and CD103 expression by OT-1 T cells derived from tumor, tumor-draining 
lymph node (dLN), and spleen of mice bearing subcutaneous B16-Ova tumors on day 14 or day 21. (B) Quantification of co-expression of VLA-1 and CD103 by 
endogenous CD8+ T cells derived from dLN, tumor, or OT-1 T cells derived from tumor. (c) Representative dot plot of VLA-1 and CD103 expression by endogenous 
CD8+ T cells derived from B16-Ova tumors. (D) Representative dot plot showing co-expression of VLA-1 and CD103 by OT-1 T cells derived from a subcutaneous 
E.G7. Numbers on FACS plots indicate percentage positive cells in each gate (a,c,D). (B) ****P < 0.0001 (one-way ANOVA, Tukey’s multiple comparisons test).
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than performing adoptive transfer of naïve OT-1 cells followed 
by subcutaneous immunization with CpG and SIINFEKL, we 
stimulated and expanded OT-1 cells in vitro prior to transfer into 
tumor-bearing mice. Analysis of OT-1 TIL from mice having 
received in vitro-stimulated cells revealed very low expression of 
both VLA-1 and CD103 compared with TIL from mice having 
been immunized with CpG and SIINFEKL peptide (Figure S2 
in Supplementary Material). This data demonstrate that adoptive 
cell transfer of in vitro-expanded TIL may generate effector cells 
which lack the expression of homing receptors important for 
tumor infiltration and retention.
Vla-1-expressing OT-1 Til are resident 
Memory T cells That are highly activated 
and exhibit superior effector Functions
Expression of CD49a, the alpha subunit of VLA-1, has previously 
been reported on virus-induced TRM cells from murine skin (17) 
and brain (28). This phenotype has not previously been inves-
tigated in the context of cancer. In our system, around 90% of 
CD103+CD69+ OT-1 TIL derived from B16-Ova tumors at day 21 
also expressed VLA-1, strongly indicating that VLA-1 is induced as 
part of the program of TRM differentiation in tumors (Figure 5A), 
similar to previous reports from models of virus infection.
CD69 is a marker of activation. A small number of CD69+ 
OT-1 T cells were also consistently found in the dLN of mice. 
Therefore, in order to distinguish between integrin expression 
induced by cellular activation or tissue infiltration, we compared 
the integrin-expression profiles of CD69+ cells in tumor (TIL) 
versus tumor-draining lymph nodes. CD69+ cells from the two 
tissue compartments showed strikingly different expression of 
VLA-1 and CD103, with only a small fraction of CD69+ OT-1 in 
dLN staining positively (Figure 5B) compared to the generalized 
expression of VLA-1 and CD103 in TIL. Together, these data 
support the notion that VLA-1 and CD103 expression on CD8+ 
TIL represents a tumor-specific adhesion phenotype, rather than 
simply an extravasated or activation-induced response.
To further investigate the functionality of integrin-expressing 
CD8+ TIL, we isolated OT-1 T cells from B16 tumor digests 
and performed in vitro re-stimulation assays. Cytokine secretion 
and degranulation of VLA-1- and CD103-expressing TIL was 
analyzed in comparison to integrin-negative TIL. We observed 
that a significantly higher proportion of OT-1 TIL expressing 
VLA-1 or co-expressing both VLA-1 and CD103 secreted IFNγ 
upon re-stimulation, as compared to their integrin-negative 
counterparts (Figure  5C). The same was true for granzyme B 
expression (Figure  5D). Finally, we quantified expression of 
the activation marker, PD-1 (29), on integrin-expressing OT-1 
FigUre 5 | Vla-1-expressing OT-1 Til are resident memory cells that are highly activated and exhibit superior effector functions. (a) Representative 
dot plot and histogram showing expression of CD69 and CD103 expression on OT-1 T cells derived from B16-Ova tumors at day 21, and VLA-1 expression by the 
CD69+CD103+ subset. (B) Expression of VLA-1 and CD103 by activated (CD69+) cells derived from tumor-draining lymph node or tumor. (c–e) Quantification of 
IFNγ secretion (c), granzyme B expression (D), and PD-1 expression (e) by integrin-positive or -negative OT-1 T cells derived from B16-Ova tumors upon ex vivo 
re-stimulation. Numbers on FACS plots indicate percentage of cells within each gate (a). (c–e) **P < 0.01, ****P < 0.0001 (one-way ANOVA, Tukey’s multiple 
comparisons test).
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TIL. Again, we observed that OT-1 TIL positive for VLA-1, or 
co-expressing both VLA-1 and CD103, were significantly more 
activated than integrin-negative OT-1 (Figure  5E). Together, 
these data indicate that expression of VLA-1 on tumor-derived 
TRM cells correlates with a higher degree of activation and 
functionality, superior to that of cells that do not exhibit this 
retention phenotype.
In Vivo Blockade of Vla-1 and cD103 
impairs control of subcutaneous  
B16-Ova Tumors
In order to assess the importance of integrin expression for tumor 
infiltration and/or functionality of CD8+ T cells, we treated mice 
bearing subcutaneous B16 tumors with function-blocking mono-
clonal antibodies against VLA-1 and CD103. Antibodies and 
OT-1 T cells were administered as indicated in Figure 6A. While 
control mice (treated with isotype antibodies) showed adequately 
delayed tumor growth, we observed significantly impaired tumor 
control in mice treated with either anti-VLA-1 (Figure  6B) or 
anti-CD103 (Figure 6C) antibodies. This impairment was more 
pronounced when VLA-1 was blocked. These results clearly 
indicate that integrin blockade targeting VLA-1 or CD103 has a 
negative impact on antitumor immunity.
DiscUssiOn
In the present study, we first sought to characterize homing recep-
tor expression by circulating melanoma-specific CD8+ T cells in 
humans. In doing so, we considered a much broader array of 
analytes than has been investigated in several previous studies 
(8, 10, 15). We found that two of the parameters analyzed, VLA-1 
expression, and P-selectin binding, correlated significantly with 
overall and DFS in a cohort of advanced melanoma patients, sug-
gesting important roles in tumor homing. We then investigated 
the expression of those analytes on CD8+ T cells derived from 
metastatic lesions from various organs including skin, lung, 
and brain. While we did not observe significant expression of 
P-selectin ligands by CD8+ TIL, we saw specific enrichment 
for cells expressing VLA-1, consistent with previous reports in 
melanoma bowel metastases (30) and head and neck tumors 
(31). Moreover, co-expression of VLA-1 together with CD69 
and CD103, the archetypal markers of TRM differentiation, was 
observed on a large proportion of cells that infiltrate tumors. To 
our knowledge, this is the first indication that TRM develop in 
tumors and display a VLA-1+CD69+CD103+ retention phenotype.
Both VLA-1 and CD103 are so-called “retention” integrins, 
proposed to underlie the long-term retention of T cells within 
peripheral tissues (16–18). They bind to distinct ligands: 
FigUre 6 | In vivo blockade of Vla-1 and cD103 impairs control of subcutaneous B16-Ova tumors. (a) Scheme illustrating engraftment, adoptive 
transfer of OT-1, and systemic treatment with integrin function-blocking monoclonal antibodies. (B,c) Growth of subcutaneous B16-Ova tumors in mice receiving 
anti-VLA-1 (B) or anti-CD103 (c) blocking antibodies or isotype control antibody injections i.p. Black arrows indicate adoptive transfer of OT-1 T cells on day 7. 
*P < 0.05, **P < 0.01 (multiple unpaired t-tests, corrected for multiple comparisons, Holm–Sidak method).
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extracellular matrix collagen in the case of VLA-1 (32) and 
epithelial E-cadherin in the case of CD103 (33). Moreover, there 
is evidence that expression of retention integrins correlates with 
superior T cell effector functions and long-term cell survival 
(34–36). Therefore, we chose to further investigate the role of 
these molecules in the antitumor immune response by means of 
a mouse tumor model.
We observed that a large proportion of adoptively transferred 
OT-1 T cells derived from B16-Ova tumors also express VLA-
1, frequently in combination with CD103, suggesting similar 
mechanisms of T cell adhesion within human and mouse tumors. 
Interestingly, this phenotype appeared 2 weeks post-transfer (but 
not earlier at 1  week). Furthermore, retention integrins were 
largely co-expressed with CD69, suggesting TRM differentiation 
status according to existing literature (16–18). Studies in murine 
models of viral infection have demonstrated that significant 
proportions of TRM cells develop 2–3 weeks after infection (17), 
consistent with the time frame in which integrin+CD69+ cells 
developed within subcutaneous tumors in our model. CD8+ 
T  cells that co-expressed VLA-1 and CD103 were virtually 
absent from tumor-draining lymph nodes and spleen, as well as 
the CD4+ T cell compartment, thus providing further evidence 
that CD8+ TRM-like cells develop specifically within tumors, an 
intriguing concept that has not been investigated to date. Since 
these are transgenic T cell receptor (TCR) T cells, the origin of 
antigen-specific TRM-like TILs is unambiguous in our system, as 
they are derived from naïve OT-1 T cells that were adoptively 
transferred into tumor-bearing mice.
Interestingly, similar TRM-like phenotypes were observed on 
OT-1 TIL regardless of whether host mice were engrafted with 
Ova-expressing B16 melanoma or E.G7 lymphoma cell lines, 
indicating that this mechanism of T cell adhesion within the tumor 
occurs beyond the context of melanoma. This finding is, however, 
in contrast to a recent report showing that antigen-specific T 
cells infiltrating subcutaneous non-small-cell lung tumors do not 
express VLA-1 (31). This discrepancy may be attributable to the 
route of vaccination used (intranasal versus subcutaneous) or the 
time point at which TIL were harvested (10 days versus 14 days 
post-vaccination). Alternatively, secretion of cytokines required 
for TRM formation, such as TGFβ and IL-15 (37), may differ in 
the microenvironment of lung tumors compared with melanoma 
and lymphoma. Our finding that TRM cells fail to develop within 
the tumors of mice receiving in vitro-expanded T cells may have 
important implications for adoptive cell transfer in the clinic. 
Specifically, considering that TRM formation is important for T 
cell-mediated antitumor immunity, as indicated by our findings 
together with recent reports in ovarian (20), lung (21), and 
bladder (22) cancer, it is noteworthy that adoptive cell transfer 
protocols (that require T cell expansion in vitro) may generate 
effector T cells with non-optimal homing receptor expression.
Finally, we observed that OT-1 TIL expressing VLA-1 and 
CD103 were more activated and displayed superior effector 
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functions to their integrin-negative counterparts. Moreover, treat-
ment of tumor-bearing mice with function-blocking monoclonal 
antibodies against either VLA-1 or CD103 in vivo led to significantly 
faster tumor growth compared to isotype control-treated mice.
To date, TRM cells have been described as a distinct subset 
of virus-specific memory T cells in non-lymphoid tissues 
(16, 38, 39), with a unique transcriptional profile (17). These cells 
are known to be long lived and have high functional potential, 
to readily secrete inflammatory cytokines and chemokines upon 
antigen rechallenge (40), and even to induce a state of “pathogen 
alert” by diverse cells in the surrounding tissue (19). In our 
study, we clearly demonstrate that TRM cells specifically develop 
within tumors (in human and mouse) in addition to models of 
viral infection, in which the current paradigm was established.
Intriguingly, VLA-1- and CD103-mediated retention of T cells 
depends on TGFβ (TGFβ induces VLA-1 and CD103 expression 
in situ) (17, 18, 41), while this cytokine is commonly described 
to suppress T cell immunity, particularly in the tumor microen-
vironment (42). In fact, it is becoming increasingly clear that the 
effects of TGFβ on CD8 T cells are dependent on the differentia-
tion subset in question, as well as the tissue and temporal context. 
While TGFβ appears to regulate the proliferation and survival of 
effector T cells during the early stages of the immune response 
(43–45), prolonged exposure to TGFβ within non-lymphoid 
tissues is required for proper development of TRM populations 
that provide front-line defense upon rechallenge (18, 44). These 
findings, in the context of the data we present here, are of sig-
nificant importance for cancer immunology. Future research 
must focus on detailed characterization of the various subsets 
and differentiation states of intratumoral T cells, with the aim to 
understand their regulation and interdependence.
Altogether, our findings reveal that P-selectin binding and 
expression of integrin VLA-1 by circulating Melan-A specific 
CD8+ T cells correlate significantly with the survival of melanoma 
patients, suggesting an important role in antitumor immunity and 
the potential to use of these analytes as biomarkers. Moreover, 
we demonstrate that VLA-1 expressing CD8+ T cells are highly 
enriched in melanoma metastases in various tissues, consistent 
with other recent reports in melanoma (30) and mucosal tumors 
in lung and head/neck (31). Within human melanoma tumors, 
VLA-1 was frequently expressed in combination with both CD69 
and CD103, the archetypal markers for TRM differentiation, as has 
been reported on virus-specific TRM from murine skin (17) and 
brain (28). We show that this phenotype is unique to the CD8+ 
TIL compartment.
Three recent reports have demonstrated that the presence of 
CD8+CD103+ TIL is associated with more favorable prognosis 
in ovarian (46), lung (21), and bladder cancer (22), but the 
importance of TRM cells for antitumor immunity remains to be 
determined. We now show that TRM cells expressing both VLA-1 
and CD103 develop in subcutaneous murine melanoma and 
lymphoma tumors within 2 weeks. These cells are highly activated 
and exhibit superior effector functions to their integrin-negative 
counterparts. Importantly, in vivo blockade of either VLA-1 or 
CD103 impairs the control of subcutaneously engrafted mela-
noma tumors. These data provide the first insight into the critical 
formation and functionality of TRM cells within tumors, which 
is of significant importance for the optimization of T cell-based 
cancer immunotherapy.
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FigUre s1 | activation status of cD8+ T cells from melanoma metastases. 
Representative flow cytometry plots showing the gating of lymphocytes of 
tumor-derived effector memory T cells from resected metastatic melanoma. 
Histograms show expression of CXCR3, CD69, and CD62L on tumor-derived 
T cells, in comparison with blood-derived cells of equivalent differentiation status.
FigUre s2 | expression of retention integrins, Vla-1, and cD103, by 
in vitro stimulated/expanded, adoptively transferred OT-1 T cells 
derived from B16-Ova tumors of mice having been subcutaneously 
vaccinated or not.
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